Avamed Synergy attends to the innovative event Transfiere 2025

Lucas Diez, CEO and Founder of the company, participated as a speaker in a roundtable discussion on precision medicine and advanced therapies.

Transfiere, the European forum for science, technology, and innovation, took place on March 12, 13, and 14. This event is a meeting point for professionals from various sectors, focused on strengthening competitiveness and sharing knowledge. It has become a key annual event for stakeholders in the ecosystem.

Avamed Synergy, the biotechnology company, attended as both an exhibitor and speaker, showcasing the latest developments of their Fluxus tool in the field of predictive oncology and precision medicine. The company had its own stand within the Research Center, where they shared cutting-edge advances and projects.

Additionally, Avamed Synergy attended in collaboration with TechFabLab, reinforcing their commitment to providing advanced solutions in the technology sector. Lucas Diez, CEO and founder of Avamed Synergy, considers the participation in Transfiere Málaga 2025 to be very positive and fruitful: "Undoubtedly, these types of events are very interesting and offer great opportunities for networking as well as learning about the latest news and innovations in the E-Health sector, particularly in innovation and funding. Without a doubt, it’s a valuable agenda that will allow us to generate new collaboration opportunities in the short term."

He also highlights the importance of attending under the TechFabLab initiative: "Being part of TechFabLab and having Avamed Synergy positioned as an active company within the hub reinforces our position as an innovative and standout company in the Valencian Community."

In parallel, Lucas Antonio Diez, CEO and founder of Avamed Synergy, participated in a roundtable on "Precision Medicine and Advanced Therapies," where current issues in the Health sector were discussed. Among the topics addressed, the challenges in artificial intelligence (AI) were explored. In this regard, Lucas Diez emphasized, "AI is transversal across all areas. In our specific field, it is essential as it overcomes many barriers and offers significant advantages in precision medicine and oncological diagnosis."

The presence at Transfiere 2025 has been a key opportunity to showcase and reinforce the company’s commitment to innovation and technological development, consolidating Avamed Synergy as a leader in the biotechnology sector.